VANCOUVER, Feb. 5, 2013 /CNW/ - Allon Therapeutics Inc. (TSX: NPC) announced today that its previously announced strategic
review has generated a number of different strategic alternatives and
opportunities that are being actively evaluated. The Company is
aggressively managing ongoing operating expenses. This strategic review
process includes considering all reasonable options for exploiting
Allon's assets as well as securing additional financing.
In addition, the Company has been informed by the Toronto Stock Exchange
("TSX") that the TSX is reviewing the eligibility for continued listing
of Allon's common shares on the TSX. The market value of Allon's
listed equity has declined to less than the required $3.0 million for a
period of 30 consecutive days. Based on the strategic review Allon
believes that a transaction, or series of transactions, are achievable
that will allow the Company to maintain its TSX listing and maximize
the value of the Company's assets.
The Company is being reviewed under the TSX's Remedial Review Process
and has been granted 120 days to comply with all requirements for
continued listing. If the Company is unable to demonstrate on or before
May 30, 2013 that it meets all TSX requirements for continued listing,
the Company's securities will be delisted 30 days from such date.
At this time, Allon intends to defend its listing. However, no
assurances can be given that the Company will be able to satisfactorily
resolve the issues which have led to the review and continue to meet
all other listing obligations and as a result, the Company's securities
may be delisted.
Allon Therapeutics Inc. is a clinical-stage biotechnology company
focused on bringing to market innovative central nervous system
therapies. The Company is listed on the Toronto Stock Exchange under
the trading symbol "NPC".
Forward Looking Statements
Statements contained herein, other than those which are strictly
statements of historical fact may include forward-looking information.
Such statements will typically contain words such as "believes", "may",
"plans", "will", "estimate", "continue", "anticipates", "intends",
"expects", and similar expressions. While forward-looking statements
represent management's outlook based on assumptions that management
believes are reasonable, forward-looking statements by their nature are
subject to known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be
materially different from any future results, events or developments
expressed or implied by them. Such factors include,
among others, the inherent uncertainty involved in scientific research
and drug development, Allon's early stage of development, lack of
product revenues, its additional capital requirements, the risks
associated with successful completion of clinical trials and the long
lead-times and high costs associated with obtaining regulatory approval
to market any product which Allon may eventually develop. Other risk
factors include the limited protections afforded by intellectual
property rights, rapid technology and product obsolescence in a highly
competitive environment and Allon's dependence on collaborative
partners and contract research organizations. Examples of forward
looking statements in this press release include statements regarding
the Company's strategic review process and the ability of the Company
to complete a transaction, or series of transactions, that will allow
the Company to meet all TSX continued listing requirements. These
factors can be reviewed in Allon's public filings at www.sedar.com and should be considered carefully. Readers are cautioned not to place
undue reliance on such forward-looking statements. Similarly, nothing
in this press release is meant to promote a pharmaceutical product or
make a regulated claim of efficacy.
SOURCE: Allon Therapeutics Inc.
For further information: